Showing results (1-10 of 45) with videos related to
Sort By:
Pageof 5
Current Treatment Options in Oncology|February 2, 2023
A League of Its Own? Established and Emerging Therapies in Undifferentiated Pleomorphic SarcomaLaurie Graves, William R Jeck, Juneko E Grilley-OlsonThe American Journal of Dermatopathology|November 6, 2020
Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating LymphocytesPaul B Googe, Kyle Flores, Francie Jenkins, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Multidisciplinary Management of Oligometastatic Soft Tissue SarcomaJuneko E Grilley-Olson, Nicholas P Webber, David S Demos, et al.The Oncologist|January 25, 2015
A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancerJuneko E Grilley-Olson, Vicki L Keedy, Alan Sandler, et al.Journal of Adolescent and Young Adult Oncology|May 19, 2021
Health Insurance Payer Type and Ethnicity Are Associated with Cancer Clinical Trial Enrollment Among Adolescents and Young AdultsRebecca D Sullenger, Allison M Deal, Juneko E Grilley Olson, et al.Current Oncology Reports|October 11, 2025
Management of Desmoid TumorsJuneko E Grilley-Olson, Gina Sotolongo, William R Jeck, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2020
A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue SarcomaSant P Chawla, Sanjay Goel, Warren Chow, et al.Targeted Oncology|October 25, 2021
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of AdministrationSiwen Hu-Lieskovan, Fadi Braiteh, Juneko E Grilley-Olson, et al.Applied Immunohistochemistry & Molecular Morphology : AIMM|August 14, 2018
Improved Tumor Purity Metrics in Next-generation Sequencing for Clinical Practice: The Integrated Interpretation of Neoplastic Cellularity and Sequencing Results (IINCaSe) ApproachNirali M Patel, Heejoon Jo, David A Eberhard, et al.JAMA Oncology|May 31, 2019
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation TrialMelissa L Johnson, Fadi Braiteh, Juneko E Grilley-Olson, et al.Pageof 5